Roburic Acid Targets TNF to Inhibit the NF-kappa B Signaling Pathway and Suppress Human Colorectal Cancer Cell Growth

Tumor necrosis factor (TNF)-stimulated nuclear factor-kappa B (NF-kappa B) signaling plays very crucial roles in cancer development and progression, and represents a potential target for drug discovery. Roburic acid is a newly discovered tetracyclic triterpene acid isolated from oak galls and exhibits anti-inflammatory activity. However, whether roburic acid exerts antitumor effects through inhibition of TNF-induced NF-kappa B signaling remains unknown. Here, we demonstrated that roburic acid bound directly to TNF with high affinity (K-D = 7.066 mu M), blocked the interaction between TNF and its receptor (TNF-R1), and significantly inhibited TNF-induced NF-kappa B activation. Roburic acid exhibited antitumor activity in numerous cancer cells and could effectively induce G0/G1 cell cycle arrest and apoptosis in colorectal cancer cells. Importantly, roburic acid inhibited the TNF-induced phosphorylation of IKK alpha/beta, I kappa B alpha, and p65, degradation of I kappa B alpha, nuclear translocation of p65, and NF-kappa B-target gene expression, including that of XIAP, Mcl-1, and Survivin, in colorectal cancer cells. Moreover, roburic acid suppressed tumor growth by blocking NF-kappa B signaling in a xenograft nude mouse model of colorectal cancer. Taken together, our findings showed that roburic acid directly binds to TNF with high affinity, thereby disrupting its interaction with TNF-R1 and leading to the inhibition of the NF-kappa B signaling pathway, both in vitro and in vivo. The results indicated that roburic acid is a novel TNF-targeting therapeutics agent in colorectal cancer as well as other cancer types.

Automated summary

The study demonstrates that roburic acid can inhibit TNF-induced NF-kappa B signaling pathway by directly binding to TNF, leading to anti-tumor and anti-inflammatory effects. It also shows potential as a therapeutic agent for colorectal cancer and other cancer types.